Trial · NCT02761057

Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed

NCT02761057, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2022-09-02

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed. Trials, record NCT02761057. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02761057

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
NCT number: NCT02761057
Status: Completed
Phases: Phase 2
Enrollment: 152 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Locally Advanced Papillary Renal Cell Carcinoma, Metastatic Papillary Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Unresectable Renal Cell Carcinoma
Interventions: Biospecimen Collection, Bone Scan, Cabozantinib S-malate, Computed Tomography, Crizotinib, Savolitinib, Sunitinib Malate
First posted: 2016-05-04
Last updated: 2025-01-13
Results first posted: 2022-09-02

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Progression Free Survival (PFS)	From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause; assessed up to 3 years	Progression is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of appropriate diameters of target lesions over smallest sum observed, or a measurable increase in a non-target lesion, or the appearance of new lesions
Secondary	Response Rate (RR)	Up to 3 years	The response rate (RR) is defined as the combined rate of confirmed and unconfirmed partial response and confirmed and unconfirmed complete response. Complete response (CR) is defined as the complete disappearance of all target and non-target lesions, along with no new lesions. Partial response (PR) is defined as \>=30% decrease of the sum of appropriate diameters of all target measurable lesions, along with no new lesions.
Secondary	Overall Survival (OS)	Up to 3 years	Duration from date of randomization to date of death from any cause.
Secondary	Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs	Duration of treatment and follow up until death or 3 years post registration	Only adverse events that are possibly, probably or definitely related to study drug are reported.
Other	MET Mutation Rate	Up to 3 years	The hazard ratio between the MET inhibitor versus (vs.) sunitinib in those with versus without the mutation (i.e., the interaction) will be compared. Response Evaluation Criteria in Solid Tumors (RECIST) response rate (confirmed and unconfirmed partial response and complete response) based on MET mutation/expression level will be compared using the chi-square test.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Progression Free Survival (PFS)	From date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause; assessed up to 3 years	Analysis population included eligible participants.	months	MEDIAN
SECONDARY	Response Rate (RR)	Up to 3 years	Analysis population included eligible participants.	percentage of participants	NUMBER
SECONDARY	Overall Survival (OS)	Up to 3 years	Analysis population included eligible participants.	months	MEDIAN
SECONDARY	Number of Participants With Gr 3 Through 5 Adverse Events That Are Related to Study Drugs	Duration of treatment and follow up until death or 3 years post registration	Eligible participants who received at least one dose of protocol treatment.	Participants	NUMBER
OTHER_PRE_SPECIFIED	MET Mutation Rate	Up to 3 years

Source ClinicalTrials.gov

Results by group276

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Progression Free Survival (PFS)	Sunitinib	5.6	95% Confidence Interval 2.9 to 6.7	months
Progression Free Survival (PFS)	Cabozantinib	9.0	95% Confidence Interval 5.6 to 12.4	months
Progression Free Survival (PFS)	Crizotinib	2.8	95% Confidence Interval 2.6 to 3.6	months
Progression Free Survival (PFS)	Savolitinib	3.0	95% Confidence Interval 2.8 to 7.2	months
Response Rate (RR)	Sunitinib	4.35		percentage of participants
Response Rate (RR)	Cabozantinib	22.73		percentage of participants
Response Rate (RR)	Crizotinib	0		percentage of participants
Response Rate (RR)	Savolitinib	3.45		percentage of participants
Overall Survival (OS)	Sunitinib	16.4	95% Confidence Interval 12.8 to 21.6	months
Overall Survival (OS)	Cabozantinib	20.0	95% Confidence Interval 11.3 to NA	months

1 to 10 of 276Source ClinicalTrials.gov

See all 276 results by group

Participant flow20

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Arm I (Sunitinib Malate)	48
Overall Study	STARTED	Arm II (Cabozantinib S-malate)	46
Overall Study	STARTED	Arm III (Crizotinib Closed to Accrual 12/5/18)	28
Overall Study	STARTED	Arm IV (Savolitinib Closed to Accrual 12/5/18)	30
Overall Study	Eligible	Arm I (Sunitinib Malate)	46
Overall Study	Eligible	Arm II (Cabozantinib S-malate)	44
Overall Study	Eligible	Arm III (Crizotinib Closed to Accrual 12/5/18)	28
Overall Study	Eligible	Arm IV (Savolitinib Closed to Accrual 12/5/18)	29
Overall Study	Received Protocol Treatment	Arm I (Sunitinib Malate)	45
Overall Study	Received Protocol Treatment	Arm II (Cabozantinib S-malate)	43

1 to 10 of 20Source ClinicalTrials.gov

See all 20 participant flow

Adverse events688

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Anemia	Blood and lymphatic system disorders	Sunitinib	17	45
other	Anemia	Blood and lymphatic system disorders	Cabozantinib	12	43
other	Anemia	Blood and lymphatic system disorders	Crizotinib	7	27
other	Anemia	Blood and lymphatic system disorders	Savolitinib	7	28
other	Blood and lymphatic system disorders - Other	Blood and lymphatic system disorders	Sunitinib	2	45
other	Blood and lymphatic system disorders - Other	Blood and lymphatic system disorders	Cabozantinib	5	43
other	Blood and lymphatic system disorders - Other	Blood and lymphatic system disorders	Crizotinib	0	27
other	Blood and lymphatic system disorders - Other	Blood and lymphatic system disorders	Savolitinib	1	28
other	Sinus bradycardia	Cardiac disorders	Sunitinib	2	45
other	Sinus bradycardia	Cardiac disorders	Cabozantinib	1	43

1 to 10 of 688Source ClinicalTrials.gov

See all 688 adverse events

Adverse event totals12

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Sunitinib	24	46
Total, all-cause mortality	Cabozantinib	22	44
Total, all-cause mortality	Crizotinib	16	28
Total, all-cause mortality	Savolitinib	21	29
Total, other adverse events	Sunitinib	44	45
Total, other adverse events	Cabozantinib	41	43
Total, other adverse events	Crizotinib	26	27
Total, other adverse events	Savolitinib	27	28
Total, serious adverse events	Sunitinib	15	45
Total, serious adverse events	Cabozantinib	19	43

1 to 10 of 12Source ClinicalTrials.gov

See all 12 adverse event totals

Papers3

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as	Source
33592176	DERIVED	PubMed
37146227	DERIVED	PubMed
39255440	DERIVED	PubMed

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U10CA180888	SWOG Network Group Operations Center of the NCTN	LARA, PRIMO N.; HERSHMAN, DAWN	UNIVERSITY OF CALIFORNIA AT DAVIS	NATIONAL CANCER INSTITUTE	2014 to 2026

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT02761057

GET https://conductscience.org/api/trials/v1/NCT02761057/results?page=2

API reference For AI assistants